Dosing
Ozempic dosage chart: a guide to the label
Ozempic is a semaglutide injection used for type 2 diabetes and specified cardiovascular and kidney-risk reduction in adults. Its chart differs from Wegovy's weight-management schedule.
How to read a dosage chart
A titration chart describes a labeled schedule, not an instruction to change your own treatment. Starter doses help introduce the medicine; the prescriber selects a maintenance dose according to the indication, response, and tolerability. Calendar weeks do not override side effects or individualized instructions.
Milligrams measure the medicine dose. Milliliters measure liquid volume, and syringe units measure markings on a particular syringe. They are not interchangeable. Never use a brand-name chart to convert a compounded vial into syringe units: concentrations differ, and the pharmacist must provide product-specific instructions.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
Labeled schedule
Ozempic is not FDA-approved specifically for chronic weight management. A prescriber may discuss off-label use, but that does not make its indication or insurance criteria the same as Wegovy's. Different pens and newer presentations need their own instructions; do not count clicks to improvise a dose.
| Stage or indication | Dose | Meaning |
|---|---|---|
| Weeks 1–4 | 0.25 mg once weekly | Introduction dose |
| After 4 weeks | 0.5 mg once weekly | Maintenance option for glycemic control |
| If additional glycemic control is needed | 1 mg after at least 4 weeks at 0.5 mg | Prescriber decision |
| If additional control is still needed | 2 mg after at least 4 weeks at 1 mg | Maximum 2 mg weekly |
| Diabetes with chronic kidney disease indication | 1 mg once weekly after initiation | Follow the indication-specific label |
Sources: Ozempic prescribing information
Missed doses and other instructions
Take a missed Ozempic dose within 5 days. If more than 5 days have passed, skip it and resume the usual schedule. For a change of weekly day, follow the label's interval of more than 48 hours between doses. This is different from tirzepatide's 72-hour interval and Wegovy's next-dose rule.
The device you receive matters. Single-dose pens, multidose pens, prefilled syringes, and vials do not use one universal injection technique. Review the Instructions for Use supplied with your product, and request training when a pharmacy changes the presentation.
Sources: Ozempic prescribing information
Safety before any dose change
These medicines have boxed warnings about thyroid C-cell tumors observed in rodents; whether the same risk occurs in humans is unknown. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. This is different from saying that every thyroid condition prevents treatment.
Review severe stomach problems, previous pancreatitis, gallbladder disease, kidney problems, diabetes-related eye disease, pregnancy plans, and all medicines with your prescriber. Insulin or sulfonylureas can increase the risk of low blood sugar when combined with these treatments. Vomiting and diarrhea can cause dehydration and kidney injury.
Severe persistent abdominal pain, inability to keep fluids down, or signs of an allergic reaction require prompt medical assessment. Do not increase a dose to overcome slow weight loss or copy another person's prescription. Tell the anesthesia team about treatment before procedures because delayed gastric emptying can affect aspiration risk.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information
The treatment goal changes the dose discussion
Ozempic's 0.25 mg starting step introduces treatment and is not intended for glycemic control. Later adult doses should be interpreted in the context of the diagnosed condition and treatment response. For additional glycemic control, the injection can progress through the labeled steps to 2 mg, with at least four weeks at the preceding dose. The kidney-risk reduction indication has its own 1 mg recommendation after initiation; choosing the largest available dose is not a substitute for reading that instruction.
Bring glucose records and details of other diabetes treatment to follow-up. Insulin and sulfonylureas can increase hypoglycemia risk when used with Ozempic, so the clinician may change their doses. Appetite suppression alone is not evidence that diabetes is adequately controlled, and a favorable weight change does not authorize stopping another prescribed medicine.
Sources: Ozempic prescribing information
Pen strength and prescribed dose are different details
An Ozempic pen contains a particular concentration and total quantity, while the prescription names the amount delivered at each injection. Read the carton and Instructions for Use together rather than treating the largest number on the box as your weekly dose. Ask the pharmacist to demonstrate dose selection, needle attachment, and the required device steps for the exact pen supplied.
Do not count pen clicks using an unofficial conversion chart or try to withdraw medicine from a pen into a syringe. A technique shared online may concern a different presentation or concentration. Pens must not be shared even if the needle is changed. If there is uncertainty about whether a dose was delivered, contact the pharmacist before repeating it; an uncertain injection is not the same as a confirmed missed one.
Sources: Ozempic prescribing information
Ozempic tablets need a different chart
The Ozempic name now also appears on daily tablets. The weekly injection chart cannot be used for those tablets, and injection doses cannot be converted by multiplying or dividing milligrams. Oral administration has its own fasting instructions and formulation strengths. The tablet label also should not be assumed to carry every indication of the injection, including the injection's kidney-risk reduction claim.
If cost, preference, or supply leads to a proposed change of route, have the prescriber specify when the old product ends and the new one starts. Review the morning timing of other oral medicines with a pharmacist. Similarly, an injectable semaglutide vial from a compounding pharmacy is not an Ozempic pen: it needs its own prescription, concentration, syringe directions, and explanation of why an approved medicine does not meet the patient's need.
Sources: Ozempic prescribing information · Rybelsus and Ozempic tablets prescribing information · FDA concerns with unapproved GLP-1 drugs used for weight loss
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.